In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Building A Biopharma Product's Reimbursement Into Deals

Executive Summary

The growing influence of payors means biopharma companies are grappling with how to incorporate the impact of reimbursement on a product’s market opportunity when structuring deals, executives said at the BIO-Windhover Pharmaceutical Strategic Outlook conference in New York City in February 2010.
Advertisement

Related Content

CER, Reimbursement Issues Drawing More Attention From Reg Professionals
Reimbursement: The New Biopharma Investment Hurdle
Reimbursement: The New Biopharma Investment Hurdle
Deals Of The Week: Charles River/WuXi, Aton/Bristol, Merck/Nycomed ...
Health Care Reform and Business Development: 10 Reasons It Matters
Health Care Reform and Business Development: 10 Reasons it Matters
WellPoint Seeks More Quality Of Life, Cost Data In Formulary Submissions

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003456

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel